Illumina, Inc. (NASDAQ:ILMN) EVP Omead Ostadan sold 3,540 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $226.91, for a total transaction of $803,261.40. Following the completion of the sale, the executive vice president now owns 26,827 shares of the company’s stock, valued at approximately $6,087,314.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Illumina, Inc. (NASDAQ:ILMN) traded down $2.39 during trading hours on Tuesday, reaching $211.06. 1,050,098 shares of the company’s stock were exchanged, compared to its average volume of 958,333. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. The company has a market capitalization of $32,885.04, a price-to-earnings ratio of 65.86, a PEG ratio of 3.72 and a beta of 0.79. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $230.72.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. The firm had revenue of $714.00 million during the quarter, compared to analyst estimates of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The company’s quarterly revenue was up 17.6% on a year-over-year basis. During the same quarter last year, the business earned $0.97 earnings per share. sell-side analysts expect that Illumina, Inc. will post 3.75 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in ILMN. Advisory Services Network LLC boosted its position in shares of Illumina by 13.0% in the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after acquiring an additional 89 shares during the period. Penserra Capital Management LLC boosted its position in shares of Illumina by 13.0% in the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after acquiring an additional 102 shares during the period. Dupont Capital Management Corp bought a new position in shares of Illumina in the third quarter valued at approximately $153,000. Paradigm Asset Management Co. LLC boosted its position in shares of Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after acquiring an additional 50 shares during the period. Finally, Patten Group Inc. boosted its position in shares of Illumina by 71.1% in the third quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock valued at $172,000 after acquiring an additional 615 shares during the period. Institutional investors own 91.75% of the company’s stock.

ILMN has been the subject of several analyst reports. Deutsche Bank upgraded shares of Illumina from a “hold” rating to a “buy” rating and lowered their target price for the company from $195.00 to $160.00 in a report on Monday, October 23rd. Canaccord Genuity reiterated a “buy” rating and issued a $230.00 target price (up previously from $215.00) on shares of Illumina in a report on Thursday, October 12th. Vetr upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $209.78 price target for the company in a research report on Wednesday, August 9th. Argus increased their price target on shares of Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday, September 13th. Finally, Bank of America increased their price target on shares of Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a research report on Wednesday, October 25th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $201.98.

WARNING: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/05/omead-ostadan-sells-3540-shares-of-illumina-inc-ilmn-stock.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.